LGI1-antibody Patients Follow-up

Clinical, EEG and Radiological Initial and Evolutive Characterisation of LGI1-antibody Patients

Status

UNKNOWN

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT04106765

Acronym

evoLGI1

Enrollment

192

Registered

2019-09-27

Start date

2019-10-30

Completion date

2020-12-30

Last updated

2019-10-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Anti-LGI1 Encephalitis

Brief summary

Autoimmune encephalitis involve autoantibodies targeting central nervous system, and particularly the synapse or its structure like for LGI1 protein. Anti-LGI1 encephalitis is revealed by an inflammation of the limbic system, with mainly temporal lobe, faciobrachial dystonic or generalized seizures, and cognitive disorders. This disease is rare and its clinical, EEG and radiological characterisation is not sufficiently established. The investigators will evaluate these three aspects for the anti-LGI1 cohort of patients of the National Reference Center of autoimmune encephalitis.

Interventions

None listed

Study design

Observational model

COHORT

Time perspective

RETROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* Age \> 18 years * Diagnosis of anti-LGI1 encephalitis based on sera or CSF samples in the National Reference Center of autoimmune encephalitis from 2011/06 to 2019 july 1st. * Clinical follow-up in France

Exclusion criteria

* Anti-LGI1 antibody associated with another encephalitis antibody * Foreign follow-up

Design outcomes

Primary

Measure	Time frame
Evolution of epileptic seizures	12 MONTHS

Countries

France

Contacts

Primary ContactJerome HONNORAT, PhD

jerome.honnorat@chu-lyon.fr4 72 35 78 08

Backup ContactGéraldine PICARD

geraldine.picard@chu-lyon.fr4 72 35 58 42

Outcome results